SecBot SecBot
8-K ·Filed Feb 25, 2026

DRMA

Dermata Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago SEC0001493152-26-008037
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any subsequent board appointments or governance changes, particularly if additional director departures occur. The resignation appears routine, but reduced board size could affect committee composition and oversight capacity.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
DRMA ▲ +0.80% at T+60d
NEUTRAL call +0.80% · α vs SPY -7.37% · entry $1.25 → $1.26
Entry = T+0 close
Feb 25, 2026
via day close
T+1d
-4.00%
call -4.00% · α -3.52%
$1.20
settled 8mo ago
T+5d
-3.20%
call -3.20% · α -2.04%
$1.21
settled 8mo ago
T+20d
+9.60%
call +9.60% · α +16.01%
$1.37
settled 7mo ago
T+60d
+0.80%
call +0.80% · α -7.37%
$1.26
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Mary Fisher resigned from Dermata Therapeutics' Board of Directors effective March 31, 2026, reducing the board size from eight to seven members. Her resignation was due to her employer being acquired and no longer permitting her to serve on the board, with no disagreement with the company.

Key Facts

  • Mary Fisher resigned from the Board of Directors effective March 31, 2026
  • Resignation was not due to any disagreement with the company
  • Fisher stepped down to comply with her employer's new policy following its acquisition
  • Board size reduced from eight to seven members
  • No replacement was named in the filing

Financial Impact

No direct financial impact disclosed

Risk Factors

  • Potential governance risk from smaller board size
  • Possible perception of instability if further board changes follow

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-008037
Document: 0001493152-26-008037-index-headers.html0001493152-26-008037
Document: 0001493152-26-008037-index.html0001493152-26-008037
Document: 0001493152-26-008037.txt0001493152-26-008037
5 reports for DRMA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for DRMA — sortable, filterable
TypeNow
Oct 21, 2026
6d ago
EFFECT
BEARISH ★ 6/10
$0.8000 $0.8640▼ −8.00%▼ −9.18%$0.7550 (+5.63%)
Oct 9, 2026
18d ago
S-3
NEUTRAL ★ 4/10
$0.8896 $0.8599▼ −3.34%▼ −3.33%$0.7550 (−15.13%)
Aug 17, 2026
10w ago
8-K
BEARISH ★ 7/10
$1.46 $1.43▲ +2.05%▲ +1.38%$0.7550 (+48.29%)
Aug 5, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$1.17 $1.11▼ −5.13%▼ −4.97%$0.7550 (−35.47%)
Feb 25, 2026
34w ago
8-K
NEUTRAL ★ 3/10
$1.25 $1.20▼ −4.00%▼ −3.52%$0.7550 (−39.60%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 9h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026